Presentation (CTI)

OBJECTIVES: With the multiple myeloma (MM) treatment landscape rapidly evolving, real-world data are key in informing clinical practice. This real-world analysis aimed to describe patients with MM, their treatment, and patient quality of life (QoL).
METHODS: Data were drawn from the Adelphi Real World MM Disease Specific Programme™, a cross-sectional survey, with retrospective data collection, of haematologists/haem-oncologists and their patients with MM in France, Germany, Italy, Spain and the United Kingdom from September 2024-March 2025. Physicians reported demographics and treatment for up-to eight consecutively consulting patients; patients self-reported QoL, including validated patient-reported outcome measures. Data were analysed descriptively.
RESULTS: Overall, 243 physicians provided data for 2083 patients with MM (509 patients self-reported data); at data collection mean (standard deviation (SD)) age was 70.9 (9.0) years, 50% were International Staging System Stage III, and 71% had an Eastern Cooperative Oncology Group Performance Status of 0-1. Of all patients, 29% had ever received a SCT at first-line, and for first-line patients at data collection (n=518), 67% were receiving a monoclonal antibody-based (MAB) triplet and 21% a proteasome inhibitor-based (PI) triplet. For second-line patients at data collection (n=566), the most common treatments were a MAB triplet (46%) and a PI triplet (22%). Mean (SD) EQ-5D-5L (Germany tariff) utility and visual analogue scale scores were 0.82 (0.16) and 65.1 (15.5) respectively. Most patients reported treatment to be between somewhat and extremely burdensome to their time in the four weeks prior to survey (88%).
CONCLUSIONS: Most patients with MM had good functioning despite being older with advanced disease. Triplet therapies were the predominant approach at first- and second-line, and SCT rates aligned with other studies. Patient-reported data underscore the need to consider the impact of living with MM on QoL in clinical decision-making. These real-world findings are important in characterising the MM landscape and may inform future therapeutic development.